Arsanis Inc (NASDAQ:ASNS) has earned a consensus rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $14.25.
Separately, ValuEngine lowered shares of Arsanis from a “buy” rating to a “hold” rating in a research note on Friday, January 4th.
Arsanis stock remained flat at $$3.11 during midday trading on Monday. 607,244 shares of the company traded hands, compared to its average volume of 62,844. Arsanis has a 52-week low of $1.15 and a 52-week high of $28.69. The firm has a market capitalization of $45.53 million, a PE ratio of -0.19 and a beta of 1.80. The company has a current ratio of 6.50, a quick ratio of 5.08 and a debt-to-equity ratio of 0.37.
Arsanis Company Profile
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Recommended Story: Trading Strategy Methods and Types
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.